|
Volumn 23, Issue 6, 1995, Pages 994-1006
|
A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: Results of a prospective, multicenter, randomized, controlled trial
a a a a a a a a a a a a a a a a a a a |
Author keywords
bacteremia; critical illness; endotoxemia; endotoxin; Gram negative bacteria; interleukin 1; monoclonal antibody; randomized clinical trial; sepsis; tumor necrosis factor
|
Indexed keywords
ANTIBIOTIC AGENT;
ENDOTOXIN;
MONOCLONAL ANTIBODY;
MONOCLONAL ANTIBODY E5;
PLACEBO;
UNCLASSIFIED DRUG;
ADULT;
ADULT RESPIRATORY DISTRESS SYNDROME;
ANTIBODY RESPONSE;
ARTICLE;
CENTRAL NERVOUS SYSTEM DISEASE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DRUG HYPERSENSITIVITY;
FEMALE;
GRAM NEGATIVE SEPSIS;
HUMAN;
INTRAVENOUS DRUG ADMINISTRATION;
MAJOR CLINICAL STUDY;
MALE;
MORTALITY;
MULTICENTER STUDY;
MULTIPLE ORGAN FAILURE;
PRIORITY JOURNAL;
PROSPECTIVE STUDY;
RANDOMIZED CONTROLLED TRIAL;
SURVIVAL;
|
EID: 0029043636
PISSN: 00903493
EISSN: None
Source Type: Journal
DOI: 10.1097/00003246-199506000-00003 Document Type: Article |
Times cited : (289)
|
References (22)
|